DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo

Area of Science:

• Molecular Biology
• Cancer Research
• Genetics

Background:

• The APOBEC3 (A3) enzyme family, known for antiviral functions, is increasingly recognized as a significant source of mutations in human cancers.
• APOBEC3-induced C-to-T and C-to-G mutations in TCA and TCT motifs are found in over 70% of human malignancies.
• Previous studies demonstrated that human APOBEC3A and APOBEC3B can promote tumor formation in vivo.

Purpose of the Study:

• To investigate the molecular mechanism underlying APOBEC3A-driven tumor development.
• To determine if APOBEC3A alone can drive tumor formation without TP53 knockdown.
• To elucidate the role of APOBEC3A's catalytic activity in tumorigenesis.

Main Methods:

• Utilized the murine Fah liver complementation and regeneration system.
• Assessed tumor development driven by APOBEC3A alone.
• Investigated the requirement of the catalytic glutamic acid residue (E72) for tumor formation.
• Examined the impact of a separation-of-function mutant with impaired DNA deamination but intact RNA editing activity.

Main Results:

• APOBEC3A alone was sufficient to drive tumor development in the murine model.
• The catalytic glutamic acid residue (E72) of APOBEC3A was essential for promoting tumor formation.
• An APOBEC3A mutant defective in DNA deamination but retaining RNA editing activity failed to promote tumor formation.

Conclusions:

• APOBEC3A acts as a "master driver" of tumor formation.
• The DNA deamination activity of APOBEC3A is the critical mechanism underlying its oncogenic potential.
• These findings highlight the direct role of APOBEC3A's enzymatic function in cancer development.